Neutralizing antibodies against SARS-CoV-2 variants after infection and vaccination

VV Edara, WH Hudson, X Xie, R Ahmed, MS Suthar - Jama, 2021 - jamanetwork.com
Methods| Serum samples were obtained from 3 groups of individuals. At Emory University,
hospitalized adults with SARS-CoV-2 infection (polymerase chain reaction confirmed) were …

Antibody response and variant cross-neutralization after SARS-CoV-2 breakthrough infection

TA Bates, SK McBride, B Winders, D Schoen… - Jama, 2022 - jamanetwork.com
Methods| Fully vaccinated health care workers subsequently diagnosed with SARS-CoV-2
breakthrough infection based on a positive polymerase chain reaction (PCR) test result were …

[HTML][HTML] The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera.

S Jangra, C Ye, R Rathnasinghe, D Stadlbauer… - MedRxiv, 2021 - ncbi.nlm.nih.gov
One year in the coronavirus disease 2019 (COVID-19) pandemic, the first vaccines are
being rolled out under emergency use authorizations. It is of great concern that newly …

Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection

RA Urbanowicz, T Tsoleridis, HJ Jackson… - Science translational …, 2021 - science.org
Understanding the impact of prior infection with severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) on the response to vaccination is a priority for responding to …

Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants

A Pegu, SE O'Connell, SD Schmidt, S O'Dell… - Science, 2021 - science.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish
vaccine-induced protective immune responses, particularly as antibody titers wane over …

SARS-CoV-2 variant Omicron: currently the most complete “escapee” from neutralization by antibodies and vaccines

M Li, F Lou, H Fan - Signal Transduction and Targeted Therapy, 2022 - nature.com
On December 23, 2021, five groups published their research results of clinical-approved
monoclonal antibodies, convalescent serum, and vaccine serum against B. 1.1. 529 …

[HTML][HTML] SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses

AC Walls, KR Sprouse, JE Bowen, A Joshi, N Franko… - Cell, 2022 - cell.com
Although infections among vaccinated individuals lead to milder COVID-19 symptoms
relative to those in unvaccinated subjects, the specificity and durability of antibody …

Neutralizing antibodies against SARS-CoV-2 variants induced by natural infection or vaccination: A systematic review and individual data meta-analysis

X Chen, Z Chen, AS Azman, R Sun, W Lu, N Zheng… - 2021 - papers.ssrn.com
Background: Recently emerged SARS-CoV-2 variants may pose a threat to immunity
derived from prototypical SARS-CoV-2 infection or vaccination. A systematic summary of the …

Change in antibodies to SARS-CoV-2 over 60 days among health care personnel in Nashville, Tennessee

MM Patel, NJ Thornburg, WB Stubblefield, HK Talbot… - Jama, 2020 - jamanetwork.com
Methods| We evaluated anti–SARS-CoV-2 antibodies at baseline and approximately 60
days later in a convenience sample of health care personnel at Vanderbilt University …

B. 1.526 SARS-CoV-2 variants identified in New York City are neutralized by vaccine-elicited and therapeutic monoclonal antibodies

H Zhou, BM Dcosta, MI Samanovic, MJ Mulligan… - MBio, 2021 - Am Soc Microbiol
ABSTRACT DNA sequence analysis recently identified the novel SARS-CoV-2 variant B.
1.526 that is spreading at an alarming rate in the New York City area. Two versions of the …